#1 Clinical Trials Search in Europe

Meropenem Anhydrous

Meropenem Anhydrous is an antibiotic being studied in various clinical trials for treating severe infections. These trials aim to evaluate its effectiveness, safety, and optimal usage in different patient populations, including those with brain abscesses, Gram-negative bacteremia, and children with malignant brain tumors. The research focuses on comparing Meropenem to other antibiotics, exploring different treatment durations, and investigating its distribution in cerebrospinal fluid.

Table of Contents

What is Meropenem Anhydrous?

Meropenem Anhydrous, also known by its brand names such as Meropenem Hikma or Meropenem Stada, is a powerful antibiotic medication[1]. It belongs to a class of antibiotics called carbapenems, which are considered “last resort” antibiotics for treating serious bacterial infections[2]. Meropenem is known by the synonym ICI-194660 in scientific literature[3].

Medical Uses

Meropenem is used to treat a variety of severe bacterial infections, including:

  • Brain abscesses: Infections in the brain that can cause serious neurological symptoms[1]
  • Gram-negative bacteremia: A serious blood infection caused by certain types of bacteria[4]
  • Infections caused by extended-spectrum beta-lactamase (ESBL) producing bacteria: These are bacteria that have developed resistance to many common antibiotics[2]
  • Severe infections in intensive care unit (ICU) patients[2]

Meropenem is particularly effective against a wide range of bacteria, including those that have become resistant to other antibiotics. This makes it a valuable tool in treating complex and life-threatening infections[2].

How is Meropenem Administered?

Meropenem is typically administered in the following ways:

  • Intravenous (IV) injection or infusion: The medication is given directly into a vein, usually in a hospital setting[1]
  • Solution for injection or infusion: Meropenem comes as a powder that is mixed with sterile water to create a solution before administration[1]

The method of administration allows the antibiotic to quickly enter the bloodstream and reach the site of infection.

Dosage Information

The dosage of Meropenem can vary depending on the type and severity of the infection, as well as the patient’s age and overall health. Some general dosage information includes:

  • For adults, the typical maximum daily dose is 6 grams per day[1]
  • For children, dosages are typically lower and based on body weight
  • Treatment duration can range from 5 to 21 days or longer, depending on the infection and the patient’s response to treatment[4]

It’s important to note that dosage should always be determined by a healthcare professional based on individual patient needs.

Current Clinical Trials

Several clinical trials are currently investigating the use of Meropenem in various scenarios:

  • A study comparing Meropenem to other antibiotics for treating brain abscesses[1]
  • Research on using Meropenem as an alternative to other antibiotics in treating severe infections caused by ESBL-producing bacteria in ICU patients[2]
  • A study examining the effectiveness of shorter antibiotic treatment durations (5 days vs. 7 or more days) for gram-negative bacteremia[4]
  • Investigation of Meropenem’s ability to penetrate the cerebrospinal fluid in children with brain tumors[3]

These trials aim to optimize the use of Meropenem and potentially expand its applications in treating various infections.

Potential Side Effects

Like all medications, Meropenem can cause side effects. Some potential side effects include:

  • Diarrhea
  • Nausea or vomiting
  • Headache
  • Rash or itching
  • Injection site reactions (pain, swelling, or redness)

In rare cases, more serious side effects can occur, such as severe allergic reactions or Clostridioides difficile infection (a type of severe diarrhea)[4]. It’s important to report any unusual symptoms to your healthcare provider promptly.

Precautions and Contraindications

Certain individuals should use Meropenem with caution or avoid it altogether:

  • People with known allergies to beta-lactam antibiotics (such as penicillins or cephalosporins)[1]
  • Pregnant or breastfeeding women (unless the potential benefits outweigh the risks)[4]
  • Patients with severe kidney problems may require dose adjustments
  • Individuals with a history of seizures, as Meropenem may increase the risk of seizures in some cases

Always inform your healthcare provider about any medical conditions, allergies, or medications you are taking before starting treatment with Meropenem.

Aspect Details
Main Conditions Studied Brain abscesses, Gram-negative bacteremia, infections in children with malignant brain tumors
Key Objectives Evaluate efficacy and safety of Meropenem, compare to other antibiotics, assess shorter treatment durations, study pharmacokinetics in cerebrospinal fluid
Patient Populations Adults with brain abscesses or Gram-negative bacteremia, children with malignant brain tumors
Dosage Forms Intravenous infusion, powder for solution for injection/infusion
Comparator Treatments Piperacillin/tazobactam, temocillin, standard duration antibiotic therapy
Primary Endpoints Mortality rates, clinical failure rates, pharmacokinetic parameters (e.g., AUC, concentration-time curves)
Safety Considerations Monitoring for adverse events, antibiotic-related complications (e.g., C. difficile infection)

FAQ

  • What is Meropenem Anhydrous? Meropenem Anhydrous is a broad-spectrum antibiotic used to treat various severe bacterial infections. It belongs to the carbapenem class of antibiotics and is typically administered intravenously.
  • What types of infections are being studied with Meropenem in these clinical trials? The clinical trials are studying Meropenem's use in treating brain abscesses, Gram-negative bacteremia (blood infections), and infections in children with malignant brain tumors.
  • How is Meropenem being compared to other treatments in these studies? In some trials, Meropenem is being compared to carbapenem-sparing agents like piperacillin/tazobactam or temocillin to assess if these alternatives are as effective in treating certain infections while potentially reducing carbapenem use.
  • What are researchers trying to learn about Meropenem's use in children? One study is investigating the pharmacokinetics of Meropenem in the cerebrospinal fluid of children with malignant brain tumors to understand how the drug is distributed and to determine appropriate dosing for these patients.
  • Are there any studies looking at shorter treatment durations with Meropenem? Yes, one trial is comparing a 5-day course of antibiotic treatment (which may include Meropenem) to the standard 7 days or more for Gram-negative bacteremia, to see if a shorter duration can be equally effective.

Ongoing Clinical Trials on Meropenem Anhydrous

  • Comparing piperacillin-tazobactam and meropenem for treating bloodstream infections caused by cephalosporin-resistant bacteria in adult patients

    Recruiting

    3 1 1 1
    Investigated drugs:
    Italy

  • Study on Antibiotics Amoxicillin, Clavulanic Acid, Ciprofloxacin, and Drug Combination for Children with Malignant Brain Tumors

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study on Shortened Antibiotic Treatment for Gram-negative Bacteremia in Hospitalized Adults Using Pivmecillinam Hydrochloride and Drug Combination

    Recruiting

    3 1 1 1
    Investigated drugs:
    Denmark

  • Study on Piperacillin-Tazobactam and Temocillin for Treating Severe Infections in ICU Patients with ESBL-Producing Gram-Negative Bacteria

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study on Oral Antibiotics Moxifloxacin, Linezolid, and Metronidazole for Patients with Bacterial Brain Abscess

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark France The Netherlands Sweden

  • A study to evaluate the use of meropenem to reduce the risk of sepsis in patients with suspected infection in the emergency department

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Greece

  • Study on the Effectiveness and Safety of Extended vs. Intermittent Infusion of Meropenem in Critically Ill Children with Suspected or Proven Infection

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Hungary

Glossary

  • Meropenem Anhydrous: A broad-spectrum antibiotic used to treat severe bacterial infections, administered intravenously.
  • Bacteremia: The presence of bacteria in the bloodstream, which can lead to serious infections throughout the body.
  • Brain abscess: A collection of pus enclosed in the brain tissue, caused by bacterial or fungal infection.
  • Carbapenem: A class of antibiotics used to treat severe or high-risk bacterial infections.
  • Cerebrospinal fluid (CSF): The clear, colorless fluid that surrounds the brain and spinal cord, protecting them from injury.
  • ESBL-producing Enterobacteriaceae: Bacteria that produce extended-spectrum beta-lactamases, enzymes that can break down many common antibiotics, making infections harder to treat.
  • Gram-negative bacteria: A class of bacteria that do not retain crystal violet dye in the Gram staining protocol, often associated with severe infections.
  • Intrathecal: Referring to the space under the arachnoid membrane of the brain or spinal cord, where cerebrospinal fluid circulates.
  • Leptomeningeal dissemination: The spread of cancer cells to the leptomeninges, the two innermost layers of tissues that cover the brain and spinal cord.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Sepsis: A life-threatening condition that occurs when the body's response to infection causes widespread inflammation and organ failure.

References

  1. http://clinicaltrials.eu/trial/study-on-oral-antibiotics-moxifloxacin-linezolid-and-metronidazole-for-patients-with-bacterial-brain-abscess/
  2. http://clinicaltrials.eu/trial/study-on-piperacillin-tazobactam-and-temocillin-for-treating-severe-infections-in-icu-patients-with-esbl-producing-gram-negative-bacteria/
  3. http://clinicaltrials.eu/trial/study-on-antibiotics-amoxicillin-clavulanic-acid-ciprofloxacin-and-drug-combination-for-children-with-malignant-brain-tumors/
  4. http://clinicaltrials.eu/trial/study-on-shortened-antibiotic-treatment-for-gram-negative-bacteremia-in-hospitalized-adults-using-pivmecillinam-hydrochloride-and-drug-combination/